Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents.
作者信息
Loo V G, Sherman P, Matlow A G
机构信息
Department of Microbiology, Hospital for Sick Children, University of Toronto, Ontario, Canada.
出版信息
Antimicrob Agents Chemother. 1992 May;36(5):1133-5. doi: 10.1128/AAC.36.5.1133.
Abstract
The in vitro activities of omeprazole and eight antimicrobial agents against 18 clinical strains of Helicobacter pylori isolated from a pediatric population were determined by an agar dilution method. Ampicillin and erythromycin were the most active agents in vitro. All strains were susceptible to azithromycin, ciprofloxacin, doxycycline, metronidazole, and tinidazole. One isolate demonstrated resistance to cefixime (MIC, greater than or equal to 4 micrograms/ml). H. pylori was inhibited by the proton pump inhibitor omeprazole.
摘要
相似文献
1
Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents.
Antimicrob Agents Chemother. 1992 May;36(5):1133-5. doi: 10.1128/AAC.36.5.1133.
2
In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole.
J Antimicrob Chemother. 1997 Dec;40(6):881-3. doi: 10.1093/jac/40.6.881.
3
Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro.
Antimicrob Agents Chemother. 1996 Jun;40(6):1531-3. doi: 10.1128/AAC.40.6.1531.
4
Potentiation of the action of metronidazole on Helicobacter pylori by omeprazole and bismuth subcitrate.
Int J Antimicrob Agents. 2000 Apr;14(3):231-4. doi: 10.1016/s0924-8579(00)00133-3.
5
Antibiotic susceptibilities of Helicobacter pylori strains isolated in the Province of Alberta.
Can J Gastroenterol. 1998 May-Jun;12(4):295-8. doi: 10.1155/1998/672746.
6
Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates.
BMC Infect Dis. 2019 Oct 22;19(1):880. doi: 10.1186/s12879-019-4536-8.
7
Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori.
J Antimicrob Chemother. 2003 Feb;51(2):439-42. doi: 10.1093/jac/dkg085.
8
Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study.
J Antimicrob Chemother. 1998 Mar;41 Suppl B:29-35. doi: 10.1093/jac/41.suppl_2.29.
9
Bactericidal activity of lansoprazole and omeprazole against Helicobacter pylori in vitro.
Arzneimittelforschung. 1998 Jun;48(6):694-7.
10
The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
Aliment Pharmacol Ther. 2004 Jun 15;19(12):1315-21. doi: 10.1111/j.1365-2036.2004.01959.x.
引用本文的文献
1
Global Profile of Drug Resistance Related to Infection in Children: A Systematic Review and Meta-Analysis.
Health Sci Rep. 2025 Sep 14;8(9):e71238. doi: 10.1002/hsr2.71238. eCollection 2025 Sep.
2
Helicobacter pylori eradication increases the serum high density lipoprotein cholesterol level in the infected patients with chronic gastritis: A single-center observational study.
PLoS One. 2019 Aug 16;14(8):e0221349. doi: 10.1371/journal.pone.0221349. eCollection 2019.
3
Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori.
Respir Res. 2017 May 30;18(1):109. doi: 10.1186/s12931-017-0594-x.
4
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.
Am J Gastroenterol. 2011 Nov;106(11):1970-5. doi: 10.1038/ajg.2011.306. Epub 2011 Oct 11.
5
Antibiotic resistance of Helicobacter pylori strains in Japanese children.
J Clin Microbiol. 2002 Feb;40(2):649-53. doi: 10.1128/JCM.40.2.649-653.2002.
6
A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.
Drug Saf. 1996 Jul;15(1):30-52. doi: 10.2165/00002018-199615010-00003.
7
Indications for treatment of Helicobacter pylori infection: a systematic overview.
CMAJ. 1994 Jan 15;150(2):189-98.
8
Gastroenterology--I: Gastroduodenal disease and Helicobacter pylori.
Postgrad Med J. 1994 Aug;70(826):561-7. doi: 10.1136/pgmj.70.826.561.
9
Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.
Drugs. 1994 Jul;48(1):91-132. doi: 10.2165/00003495-199448010-00008.
10
Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.
Drugs. 1992 Nov;44(5):750-99. doi: 10.2165/00003495-199244050-00007.
本文引用的文献
1
Pyloric Campylobacter infection and gastroduodenal disease.
Med J Aust. 1985 Apr 15;142(8):439-44. doi: 10.5694/j.1326-5377.1985.tb113444.x.
2
Attempt to fulfil Koch's postulates for pyloric Campylobacter.
Med J Aust. 1985 Apr 15;142(8):436-9. doi: 10.5694/j.1326-5377.1985.tb113443.x.
3
Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH.
Am J Gastroenterol. 1987 Mar;82(3):192-9.
4
Campylobacter pyloridis-associated primary gastritis in children.
Pediatrics. 1987 Aug;80(2):192-5.
5
Association of Campylobacter pylori on the gastric mucosa with antral gastritis in children.
N Engl J Med. 1987 Jun 18;316(25):1557-61. doi: 10.1056/NEJM198706183162501.
6
Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents.
Eur J Epidemiol. 1988 Jun;4(2):154-7. doi: 10.1007/BF00144743.
7
8
Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents.
Antimicrob Agents Chemother. 1985 Dec;28(6):837-8. doi: 10.1128/AAC.28.6.837.
9
Interpretative criteria for the agar diffusion susceptibility test with azithromycin.
J Antimicrob Chemother. 1988 Nov;22(5):637-41. doi: 10.1093/jac/22.5.637.
10
Long-term storage of Campylobacter pylori.
J Clin Microbiol. 1989 Jul;27(7):1655-6. doi: 10.1128/jcm.27.7.1655-1656.1989.
Zotero 插件